CLL Prognosis Is Better Captured by Molecular Markers Than Genomic Complexity

High-risk molecular features may provide stronger prognostic discrimination than genomic complexity in chronic lymphocytic leukemia (CLL), according to a recent analysis of clinical trial cohorts in the United Kingdom.¹ The findings, published in Leukemia, suggest that reliance on copy number–based measures of genomic complexity alone may be insufficient for contemporary risk stratification and could be superseded by integrated molecular profiling.

The retrospective study included 495 previously untreated patients with CLL enrolled in 3 randomized clinical trials evaluating chemotherapy and immunotherapy in the United Kingdom: phase 3 CLL4 (NCT00004218), phase 2b ADMIRE (ID6897), and phase 2b ARCTIC (ID7136). Investigators evaluated the prognostic relevance of genomic complexity, defined by the number of copy number alterations (CNAs), alongside established and emerging molecular markers. Patients were categorized as having low (≤ 2 CNAs), intermediate (3 or 4 CNAs), or high genomic complexity (≥ 5 CNAs).

Although high genomic complexity has historically been associated with inferior outcomes and correlated with progression-free survival (PFS) and overall survival (OS) in certain univariate models in the study, its independent prognostic value diminished when adjusted for high-risk molecular features, only remaining an independent predictor of overall survival in the CLL4 cohort (HR, 1.61; P =.02).

In contrast, molecular features continued to stratify outcomes across genomic complexity subgroups in the trials, suggesting that these features may capture underlying disease biology more directly. Specifically, the analysis found that unmutated IGHV status demonstrated stronger and more consistent associations with PFS in the ARCTIC and ADMIRE (HR, 2.04; P = .0001) and CLL4 (HR, 1.94; P < .01) cohorts. Similarly, TP53 aberration independently predicted shorter PFS across the studies, with an HR of 3.59 (P <.001) in ARCTIC and ADMIRE and a 2.68 HR (P = .01) in CLL4.

For OS, TP53 aberration was an independent predictor in ARCTIC and ADMIRE (HR, 2.91; P = .002) and CLL4 (HR, 2.94; P < .001). Other molecular markers that independently predicted OS included n-CLL and age in ARCTIC and ADMIRE; and trisomy 12 (Tri12), telomere length short (TL-S), unmutated CLL (U-CLL), SF3B1 mutations, and age in CLL4.

“In conclusion, our findings support a model in which [high genomic complexity] reflects an accumulation of adverse biological features in CLL, including TP53 aberration, telomere shortening, and unmutated IGHV status, particularly among those cases with the most naive-like epigenetic profiles,” the authors wrote. “Future efforts should focus on longitudinal profiling to map the dynamics of complexity acquisition with telomere attrition in cases characterized at the epigenetic level, along with further validation of our findings in targeted therapy-treated cohorts.”

Implications for Prognostic Stratification in the Targeted Era

Of note, the study population was derived from patients treated during the chemoimmunotherapy era, raising questions about the applicability of genomic complexity to targeted therapies. Prior studies have suggested that certain high-risk cytogenetic features may have a less pronounced prognostic impact with newer agents, such as Bruton tyrosine kinase inhibitors or BCL2 inhibitors. However, molecular characteristics such as TP53 disruption and IGHV mutation status remain clinically relevant across treatment modalities.

The findings have potential implications for clinical trial design and routine practice. Risk stratification models that prioritize molecular features over aggregate genomic complexity may better identify patients at highest risk for disease progression and inform therapeutic decision-making. In particular, incorporation of telomere length and mutational profiling could refine selection criteria for time-limited vs continuous therapy approaches.

The authors note that genomic complexity may still hold value in specific contexts, particularly when defined using standardized methodologies and thresholds. However, variability in CNA detection techniques and cutoffs has limited its reproducibility across studies. By contrast, molecular assays for IGHV mutation status and targeted sequencing are increasingly standardized and widely available.

Limitations of the analysis include its retrospective design and the use of trial cohorts that may not fully reflect real-world populations. Additionally, the absence of patients treated with exclusively targeted agents may limit applicability to current frontline management. Prospective validation in modern therapeutic settings will be necessary to confirm these findings.

Nonetheless, the study contributes to a growing body of evidence supporting a transition from cytogenetic to molecular risk models in CLL. As therapeutic options expand and outcomes improve, precise risk stratification will remain essential for optimizing patient selection and treatment sequencing.

REFERENCE

1. Parker H, Carr L, Norris K, et al. High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights. Leukemia. 2026;40(4):816-826. doi:10.1038/s41375-026-02906-5